https://en.wikipedia.org/wiki/Antibody-dependent_enhancement
A perspective on potential antibody-dependent enhancement of SARS-CoV-2
https://www.nature.com/articles/s41586-020-2538-8
The TL;DR good news version seems to be that
In summary, current clinical experience is insufficient to implicate a role for ADE of disease, or immune enhancement by any other mechanism, in the severity of COVID-19.
Prospective studies that relate the kinetics and burden of infection and the host response—including the magnitude, antigen-specificity and molecular mechanisms of action of antibodies, antibody classes and T cell subpopulations—to clinical outcomes are needed to define the characteristics of a beneficial compared with a failed or a potentially detrimental host response to SARS-CoV-2 infection.
Although it will probably continue to be difficult to prove that ADE of disease is occurring, or to predict when it might occur, it should be possible to identify correlates of protection that can inform immune-based approaches to the COVID-19 pandemic
https://en.wikipedia.org/wiki/Antibody-dependent_enhancementA...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.10 |
Change
-0.035(3.10%) |
Mkt cap ! $1.250B | |||
| Open | High | Low | Value | Volume |
| $1.12 | $1.14 | $1.09 | $4.321M | 3.902M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 50637 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 59529 | 18 |
View Market Depth
| Last trade - 10.57am 09/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.10 |
Change
-0.035 ( 3.00 %) |
||||
| Open | High | Low | Volume | ||
| $1.12 | $1.14 | $1.09 | 919972 | ||
| Last updated 11.16am 09/05/2024 ? | |||||
| MSB (ASX) Chart |